Novo real-world studies link Wegovy® 2.4 mg to reductions in liver enzymes, weight, and blood sugar in adults with MASH at The Liver Meeting® (AASLD) 2026
A company-issued PR Newswire release relevant to peptide research or development. Treat claims as preliminary unless confirmed by peer-reviewed evidence or an official regulator.
Open original source ↗Collected Nov 6, 2026. Third-party data may change. Consult the original publication or registry for complete methods, findings and status.